#### **AGENDA**

## NCI Workshop on Criteria for Use of Omics-Based Predictors in Clinical Trials

## **THURSDAY, JUNE 23**

7:30-8:00 REGISTRATION & CONTINENTAL BREAKFAST

8:00-8:15 WELCOME & OPENING REMARKS

Barbara A Conley, MD

8:15-8:30 NCI PERSPECTIVE & OVERVIEW OF GOALS

Lisa M McShane, PhD

8:30-9:10 KEYNOTE ADDRESS

James H Doroshow, MD

9:10 -9:30 WHEN IS A PREDICTOR CLINICALLY USEFUL?

Michael J Birrer, MD PhD

9:30-10:30 PANEL DISCUSSION: CHALLENGES IN SPECIMEN QUALITY AND HANDLING

Organizer & Moderator: David Eberhard, MD PhD

Panelists:

Sunil Badve, MD

Stephen M Hewitt, MD PhD

Andrea L Richardson, MD PhD

Reena Philip, PhD

10:30-10:45 COFFEE BREAK

10:45-11:45 PANEL DISCUSSION: ASSAY CHALLENGES, PITFALLS, AND SOLUTIONS

Organizer & Moderator: Mickey Williams, PhD and William L Bigbee, PhD

Panelists:

Daniel Chan, PhD

Patrick Hurban, PhD

Char	lρς	ΛЛ	Perou.	PhD
CHUH	CO	IVI	r crou.	I

Donna Roscoe, PhD

Leming Shi, PhD

1	1	٠Δ	5-	12	٠.4	5		ш	N	CI	н
4		.4			4		ш	u	IV	•	

## 12:45-1:05 SAMPLE REUSE IN LARGE SCALE GENE EXPRESSION STUDIES

Paul T Spellman, PhD

# 1:05-1:25 OVERVIEW OF MODEL BUILDING STRATEGIES AND PERFORMANCE ASSESSMENT METHODS

Jeremy M G Taylor, PhD

## 1:25-1:40 ASSESSING ANALYTIC REPRODUCIBILITY OF PREDICTIONS

Kevin K Dobbin, PhD

#### 1:40-2:00 BLINDED CLINICAL VALIDATIONS - ROLE OF HONEST BROKER

Michael LeBlanc, PhD

# 2:00-3:00 PANEL DISCUSSION: DOCUMENTATION, ROBUSTNESS, AND REPRODUCIBILITY OF COMPUTATIONAL MODELS, INCLUDING THE APPROPRIATE SOURCE DATA

Organizer & Moderator: Jill P Mesirov, PhD

Panelists:

Keith Baggerly, PhD

Robert L Becker, MD

Roger Peng, PhD

Paul T Spellman, PhD

Pablo Tamayo, PhD

## 3:00-3:20 CLINICAL TRIAL DESIGNS FOR EVALUATING OMICS-BASED PREDICTORS

Richard M Simon, DSc

## 3:20-3:45 REGULATORY REQUIREMENTS

Robert L Becker, MD

Lisa D White, PhD

#### 3:45-4:00 COFFEE BREAK

## 4:00-5:30 BREAKOUT GROUPS

- A. Specimen Issues
- B. Assay Issues
- C. Model Development, Specification, and Retrospective Performance Evaluation
- D. Prospective Phase II and Phase III Clinical Trial Design and Data Stewardship in Clinical Trials
- E. Regulatory and Legal Issues

# FRIDAY, JUNE 24

#### 7:30-8:00 CONTINENTAL BREAKFAST

## 8:00-11:35 PRESENTATIONS BY BREAKOUT GROUPS

(25 min. presentation of recommendations +15 min. floor discussion for each group)

8:00-8:40	BREAKOUT GROUP A
8:40-9:20	BREAKOUT GROUP B
9:20-10:00	BREAKOUT GROUP C
10:00-10:15	COFFEE BREAK
10:15-10:55	BREAKOUT GROUP D
10:55-11:35	BREAKOUT GROUP E

#### 11:35-12:00 GENERAL FLOOR DISCUSSION AND WRAP-UP